JB Chemicals secures USFDA nod for generic version of Clartin tablet
Mumbai: Drug major, J.B. Chemicals & Pharmaceuticals Limited, has recently announced that the U.S. Food and Drug Administration (USFDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use.
This product is generic version of Clartin tablet in the same strength of Bayer Healthcare LLC.
The Company expects to commercialize this product in Ql of FY 2021-22 and is expected to improve Company's US sales.
Established in 1976 by Shri J.B. Mody, J. B. Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India's fastest-growing pharmaceutical company, with its popular gastro products like Metrogyl & Rantac. The company is also having anti-hypertensive range in India with commonly prescribed formulations such as Nicardia (Nifedipine), Cilacar (Cilnidipine) and with recent launch of Azovas (Azelnidipine) it has acquired a nickname in the pharmaceutical industry as the "House of CCBs".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.